Compare Summit Therapeutics Inc (SMMT) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs ProShares Ultra Gold ETF — how do they compare? Summit Therapeutics Inc trades at $17.44 (market cap $13.71B), while ProShares Ultra Gold ETF trades at $46.55 (market cap $716.59M). The key difference: Summit Therapeutics Inc is far larger — about 19.1× ProShares Ultra Gold ETF's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and ProShares Ultra Gold ETF for 23 Days on average.
| SMMT | UGL | |
|---|---|---|
Market Cap | $13.71B | $716.59M |
Volume | 6,173,057 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $26.38 | $85.62 |
52-Week Low | $12.43 | $42.79 |
Typical Hold Time | 16 Days | 23 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
UGL trades at $46.24, up 4.07% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $46 and support at $45. Financial ratios are unavailable, limiting fundamental assessment. Recent gold-related news highlights volatility from Treasury yields and Fed policy, influencing sentiment.
Outlook remains cautious due to bearish technicals and macroeconomic pressures. Risks include interest rate sensitivity and lack of financial transparency. Investors should await earnings reports for fundamental clarity amid current market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
